Thyrocare Technologies has signed a Business Transfer Agreement for purchase of the diagnostic and pathological services business of Vimta Labs.
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 crore in Q1 FY 2025.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
